Empagliflozin Normalizes Fasting Hyperglycemia and Improves Postprandial Glucose Tolerance in Totally Pancreatectomized Patients: A Randomized, Double-Blind, Placebo-Controlled Crossover Study
Authors' conclusion
Empagliflozin administered the day before and immediately before a standardized liquid mixed meal test normalized fasting hyperglycemia and improved postprandial glucose tolerance in pancreatectomized patients.
Study context
- Population
- 10 totally pancreatectomized patients and 10 matched healthy control participants; basal insulin as usual, bolus insulin omitted before meal test10 patients + 10 controls
- Comparison
- Empagliflozin 25 mg vs placebo before a liquid mixed meal test
Methodological detailsdouble-blind, placebo-controlled, crossover
- Double-blind
- Placebo-controlled
- Crossover
Primary result
As reported in the abstract
FPG in pancreatectomized patients
P = 0.007
Further findings
Postprandial plasma glucose excursions (baseline-subtracted AUC) in pancreatectomized patients · 3-h meal test · lower with empagliflozin
P = 0.014
FPG in control participants · lower with empagliflozin
P = 0.008
FPG in control participants
- Postprandial glucose excursions not significantly affected in controls
Postprandial glucagon excursions
- Greater in pancreatectomy group vs controls on both experimental days
- P ≤ 0.015
- No within-group differences between days
Original publication
Empagliflozin Normalizes Fasting Hyperglycemia and Improves Postprandial Glucose Tolerance in Totally Pancreatectomized Patients: A Randomized, Double-Blind, Placebo-Controlled Crossover Study. Diabetes Care. Published 13 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →